Prior research in both solid tumors and hematological cancers already demonstrated an important role of S100A9 in cancer progression and drug resistance (e.g. chemotherapy, radiotherapy and immunotherapy resistance) [31]. This evidence concerns the gene S100A9 and hematopoietic and lymphoid cell neoplasm.